Qube Research & Technologies (QRT)
CLYM

Qube Research & Technologies (QRT)’s Climb Bio CLYM Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$714K Buy
104,217
+69,621
+201% +$402K ﹤0.01% 2623
2025
Q4 		$138K Sell
34,596
-2,006
-5% -$4.82K ﹤0.01% 3132
2025
Q3 		$73.6K Buy
36,602
+2,292
+7% +$4.26K ﹤0.01% 3115
2025
Q2 		$42.5K Buy
+34,310
New +$42.7K ﹤0.01% 3182
2024
Q2 		– Sell
-981
Closed -$2.69K – 4882
2024
Q1 		$2.69K Hold
981
– – ﹤0.01% 3968
2023
Q4 		$2.63K Hold
981
– – ﹤0.01% 3798
2023
Q3 		$2.59K Buy
+981
New +$2.67K ﹤0.01% 3545
2022
Q2 		– Sell
-15,874
Closed -$133K – 3230
2022
Q1 		$133K Buy
+15,874
New +$148K ﹤0.01% 2026

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CLYM Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Climb Bio (CLYM) stake by 201% in Q1 2026, buying an estimated $402K and bringing the position to 104,217 shares worth $714K. The position accounts for ﹤0.01% of the portfolio, ranked #2623.

Qube Research & Technologies (QRT) first reported a position in CLYM in Q1 2022 and has held it in 8 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Qube Research & Technologies (QRT) held 104,217 shares of Climb Bio worth $714K as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 69,621 Climb Bio shares in Q1 2026, an estimated $402K.
  • Climb Bio made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2623 holding.
  • Qube Research & Technologies (QRT) first reported a position in Climb Bio in Q1 2022 and has held it in 8 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.